# Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

> **NCT00508924** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 140 (actual)

## Conditions studied

- Coronary Artery Disease
- Angina, Unstable

## Interventions

- **DRUG:** Argatroban
- **DRUG:** Argatroban
- **DRUG:** Argatroban
- **DRUG:** Heparin

## Key facts

- **NCT ID:** NCT00508924
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508924, "Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00508924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*